IASIS PHARMA has launched a new pharmaceutical product under the brand name Contrahist (as levocetirizine dihydrochloride). It is a non-sedative antihistamine and is available as 5 mg-strength f.c tablets and a 0.5 mg/mL oral solution. Contrahist is the 1st generic levocetirizine, which has been successfully launched in the Greek pharmaceutical market by a Greek pharmaceutical [...]

IASIS PHARMA has launched a new pharmaceutical product under the brand name Licepler (Eplerenone). Licepler is specifically indicated for the reduction of risk of cardiovascular death in people with heart failure and left ventricular dysfunction ≤40% after a recent acute myocardial infarction, in combination with standard therapies and as treatment against hypertension. Licepler (25mg/f.c. tab [...]

IASIS PHARMA has launched a new pharmaceutical product under the brand name Venlaxin. The active ingredient of Venlaxin is venlafaxine, approved for the treatment of MajorDepressive Disorder.  Venlaxin prolonged release tablets (PR tabs) utilize a unique osmotic tablet technology to specifically address the once daily delivery of the drug. This unique osmotic tablet technology allows [...]

IASIS PHARMA has launched a new pharmaceutical product under the brand name Avalsan plus. Avalsan plus film-coated tablets contain two active substances namely, valsartan and hydrochlorothiazide in the following strengths: (80+12,5)mg/tab and (160+25)mg/tab. Both substances help to control high blood pressure (hypertension). Avalsan plus is used to treat high blood pressure which is not adequately [...]

IASIS PHARMA has launched a new pharmaceutical strength (320mg/tab) to enhance the brand name Avalsan (Valsartan). Avalsan is the 1st generic Valsartan, which has been successfully launched in the Greek pharmaceutical market in all pharmaceutical strengths: 80mg/tab, 160mg/tab and 320 mg/tab.

IASIS PHARMA has launched a new pharmaceutical product under the brand name Αxibal (Ibandronic acid). Αxibal 150mg f.c. tabs, is indicated for the treatment and prevention of osteoporosis in post-menopausal women. The simple dosage regimen (Once monthly) improves the patient compliance in the treatment of osteoporosis.

IASIS PHARMA has launched a new pharmaceutical product under the brand name Calciform D3. It is the original form of Ca + Vit D (Calcium carbonate+ Cholecalciferol: 1000mg+880 IU) in effervescent tablets. The addition of Calciform D3 is the obvious choice as an adjuvant treatment for osteoporosis. The easiest intake pharmaceutical form High absorption Complete [...]